PD-1/PD-L1-IN-24

Cat. No.:	HY-144649
CAS No.:	2667680-33-1
Molecular Formula:	$C_{34}H_{30}ClN_5O_6$
Molecular Weight:	640.08
Target:	PD-1/PD-L1
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PD-1/PD-L1-IN-24 is a highly potent PD-1/PD-L1 inhibitor with IC_{50} value of 1.57 nM. PD-1/PD-L1-IN-24 can restore T-cell function at the cellular level by significantly elevating the IFN-γ level. PD-1/PD-L1-IN-24 has low toxicity on the PBMCs[1].
IC_{50} & Target	IC_{50}: 1.57 nM (PD-1/PD-L1)[1]
In Vitro	PD-1/PD-L1-IN-24 (compound 39) (0-10 μM; 6 hours) significantly releases PD-L1-mediated inhibition of PD-1-expressing Jurkat T cells at the concentration of 10 μM[1]. PD-1/PD-L1-IN-24 (0.003-20 μM; 72 hours) exhibits no significant toxicity at concentrations ranging from 0.003 to 2.22 μM, and the IC_{50} is 12.42 μM[1]. PD-1/PD-L1-IN-24 (0.082, 0.247, 0.741 and 2.222 μM; 72 hours) significantly elevates the secretion of IFN-γ with a dose-dependent manner in T cell-tumor co-culture cells[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay

Cell Line:	PBMC[1]
Concentration:	0.003, 0.0091, 0.027, 0.082, 0.247, 0.741, 2.222, 6.67 and 20 μM
Incubation Time:	72 hours
Result:	No significant toxicity was observed at concentrations ranging from 0.003 to 2.22 μM, and the IC_{50} was 12.42 μM.

REFERENCES

[1]. Wang Y, Kun Huang, Gao Y, et al. Discovery of quinazoline derivatives as novel small-molecule inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction. Eur J Med Chem. 2022;229:113998.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA